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Antibody-inducing  vaccines  are  a major  focus  in  the  preventive  HIV vaccine  ﬁeld.  Because  the  most
common  tests  for  HIV  infection  rely  on  detecting  antibodies  to HIV,  they may  also  detect  antibodies
induced  by  a  candidate  HIV  vaccine.  The  detection  of  vaccine-induced  antibodies  to  HIV  by  serological
tests  is  most  commonly  referred  to  as vaccine-induced  sero-reactivity  (VISR).  VISR  can  be misinterpreted
as  a  sign  of  HIV  infection  in  a healthy  study  participant.  In  a participant  who  has  developed  vaccine-
induced  antibodies,  accurate  diagnosis  of  HIV infection  (or  lack  thereof)  may  require  specialized  tests
and  algorithms  (differential  testing)  that  are  usually  not  available  in community  settings.  Organizations
sponsoring  clinical  testing  of  preventive  HIV  vaccine  candidates  have  an  ethical  obligation  not  only  toaccine-induced sero-positivity
accine-induced sero-reactivity
ISR
ISP
inform  healthy  volunteers  about  the  potential  problems  associated  with  participating  in a clinical  trial  but
also to help  manage  any  resulting  issues.  This  article  explores  the scope  of VISR-related  issues  that  become
increasingly  prevalent  as  the  search  for  an  effective  HIV  vaccine  continues  and  will be paramount  once
a  preventive  vaccine  is  deployed.  We  also  describe  ways  in  which  organizations  conducting  HIV vaccine
trials  have  addressed  these  issues  and  outline  areas  where  more  work  is needed.
©  2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/3.0/).
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. Scope of the problem
The detection of vaccine-induced antibodies to HIV by sero-
ogical tests is most commonly referred to as vaccine-induced
ero-reactivity (VISR)2 or vaccine-induced sero-positivity (VISP)
Fig. 1). While eliciting broadly-reactive, long-lasting antibody
esponses to HIV is generally viewed as desirable for HIV vaccine
andidates [1–5], trial participants that develop antibodies to HIV
nd, as a result, VISR status, may  experience a number of chal-
enges in their day-to-day life. Social harms associated with VISR
ave included disruption of personal relationships; difﬁculties in
nding or keeping employment; difﬁculties in obtaining insurance;
mpediments to travel; inability to enlist into the military; inabil-
ty to donate blood, sperm, and organs; and inappropriate medical
reatment (Table 1).
In clinical studies, the frequency of VISR has varied extensively
epending on several factors (Table 2). The proﬁle of the elicited
mmune responses and resulting VISR is affected by various charac-
eristics of the HIV vaccine candidates, such as the viral components
eing targeted and the delivery technologies used. Small changes
n vaccine regimens, such as the dose of a single component, may
ffect VISR frequency. In addition, duration of VISR status is also
ery variable. In some cases HIV antibody responses have persisted
or more than 20 years after vaccination [6].
Commercially available tests have different speciﬁcity and sen-
itivity, which may  result in different VISR outcomes. A study
articipant who tested sero-negative at the time of study exit may
till harbor HIV antibodies that could be detected by different or
ewly available tests. Therefore a negative VISR status at the end
f a study does not guarantee that a participant will not need dif-
erential testing in the future.
While developing antibodies to HIV does not result in physiolog-
cal harm, the evolution of the HIV diagnostic and vaccine research
elds have created the potential for negative social impacts for indi-
iduals with such vaccine-induced antibodies. This situation can be
ddressed on two fronts: changes in diagnostic technologies and
easures to prevent or mitigate social harms.
. Technical approaches to differentiate vaccine-induced
esponses from infection
The confounding effects of VISR on HIV diagnostics are due to
he fact that these tests are based on detection of antibodies (Fig. 1).
lthough the fourth generation of diagnostic HIV tests includes
etection of viral antigens, they continue to detect antibodies and,
herefore, are unlikely to address VISR challenges [7,8].
One way to prevent the complications of VISR is to develop tests
hat detect non-vaccine antibody responses or viral components,
uch as proteins, RNA, or DNA and to promote their use in commu-
ity settings. Several small companies are making good progress
oward differential tests. One such example is HIV-Selectest [9–11],
hich is being developed by Immunetics, Inc. HIV-Selectest detects
ntibodies to a region in gp41 that is rarely included in vaccine
mmunogens and can therefore be used for differential serologic
2 It has been suggested that the terms VISP and VISR could be obscure or
ven stigmatizing (when the word ‘positive’ is perceived as an HIV-infected sta-
us). Community consultations conducted by the Global HIV Vaccine Enterprise
n  US and Kenya echoed this concern. However, in a discussion organized by
he  Global HIV Vaccine Enterprise, representatives from ten HIV vaccine research
rganizations around the world agreed that VISP and VISR present the best
ption to maintain historical continuity in bibliographical searches in the con-
ext  of research publications. New terms, such as ‘vaccine-induced antibodies’
r  ‘vaccine antibody response’, should be considered for dialogue with the pub-
ic. To see the full report on the consultation and existing nomenclature guide,
isit: http://www.vaccineenterprise.org/content/timely-topic-VISP. In this paper,
he  term VISR is used to refer to this phenomenon.15) 1243–1249
testing. HIV-Selectest has been tested against specimens from a
number of clinical trials with good results [11,12].
With regard to detecting viral components, monoclonal anti-
bodies can be used to detect viral proteins, such as capsid protein
(p24), in the blood, but tests based on this strategy must overcome
the challenge of plasma antibodies competing with the assay anti-
body. Detection of HIV RNA by quantitative PCR is highly accurate
and is used in management of HIV disease. However, this assay is
complex, expensive, and may  give false-negative results in indi-
viduals who naturally control viral load or are on ARV medications.
Qualitative nucleic acid (DNA or RNA or both) assays face similar
challenges, but may  provide a cheaper and more reliable alterna-
tive. The only nucleic acid-based diagnostic test for HIV infection
approved by the US Food and Drug Administration (FDA) is the
Aptima HIV-1 RNA assay (Hologic), and there are few point-of-care
nucleic acid-based diagnostic tests in development.
In addition to the challenge of technological feasibility, the tests
must be adaptable to low-resource settings where electricity and
cold chain are not always available. These technologies must also be
portable, easy to use with little training, and inexpensive to oper-
ate. From a regulatory perspective, the FDA considers HIV tests
as Class III devices (i.e., high-risk medical devices), which is the
most stringent regulatory category [13]. Therefore the develop-
ment of differential HIV tests capable of distinguishing VISR from
HIV infection entails more regulatory and logistical complexities
than other diagnostic areas, discouraging large diagnostic compa-
nies from investing in such specialized tests.
Licensure of an HIV vaccine would drastically increase the need
for differential testing. However, in the absence of a widely avail-
able HIV vaccine, serological tests are likely to remain the primary
diagnostic approach. Thus, it is highly unlikely that the challenges
that trial participants with VISR face in the community will have
simple/rapid technological solutions in the near future. Therefore,
it is up to the organizations sponsoring these studies to help study
participants avoid social harm by offering support and state-of-the
art diagnostic testing.
3. Current practices and areas for improvement
The issues associated with VISR have been recognized for years,
and organizations conducting clinical HIV vaccine studies are
addressing them to various degrees. The solutions can be divided
into four general categories: (a) educate participants of the poten-
tial for VISR and how it may impact their lives, (b) provide ongoing
differential testing for former vaccine trial participants who  have
VISR, (c) help manage any social harms that occur as a result of
the participant’s VISR status, and (d) educate the investigators,
community, healthcare providers about VISR. A survey of nine orga-
nizations conducting HIV vaccine clinical trials showed that while
the most essential of these activities are implemented by many of
the organizations, other activities are less widespread or need to
be reﬁned (Table 3).
3.1. Educate study participants about VISR
All surveyed organizations provide information to study partic-
ipants about the existence of VISR at the time of informed consent.
The participants are told that they should be tested for HIV infec-
tion only at clinical research sites (CRS) and strongly advised against
community-based testing. The participants are informed that VISR
may  persist for prolonged periods of time, perhaps years, and that
the study organization or sponsor will provide long-term support to
ensure accurate testing and to address any resulting social harms.
At the end of study, participants with VISR status are counseled to
contact their CRS before any community-based HIV testing and to
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big. 1. Results of commonly used serology-based tests are inconclusive with regard
accine-induced antibodies and antibodies present as a result of an HIV infection. T
he  person with vaccine-induced antibodies could still become infected with HIV, V
nform their regular doctor about their participation in a vaccine
tudy. However, according to recommendations for HIV testing by
he Centers for Disease Control and Prevention, individuals can be
ested for HIV under a general consent for all medical care and that
re-test counseling is not required as part of screening programs
n healthcare settings [14]. While individuals can “opt-out” of HIV
esting, the process may  be confusing for some, especially if they
re not aware of this practice beforehand and/or present at a hospi-
al for an emergency. The availability of over-the-counter in-home
ests may  further exacerbate these HIV testing challenges.
Recommended: trial sponsors to strongly advise all participants
o inform their primary care physician about their participation in
n HIV vaccine trial and the possibility of VISR.
.2. Providing accurate testing in the long term
At the end of the study, participants are tested for HIV infection
sing study-speciﬁc diagnostic algorithms and for VISR using diag-
ostic serologic kits used in the community. This service is provided
y all organizations surveyed.
Commercially available tests are constantly evolving, and new
ests may  have different speciﬁcity or sensitivity for detecting
accine-induced antibodies. Alternatively, participants may  relo-
ate to a community where different commercial HIV screening
ests are used, which could also lead to a change in VISR status.
herefore, all trial participants, even those without VISR at the end
f study, may  need differential testing in the future.
Differential testing after the trial is typically managed through
he CRS. If participants move away from their original study site,
ccess to long-term testing may  be compromised. If no other CRS
xists near a relocated participant, arrangements have to be made
o draw blood and to ship the samples back to the organization
r afﬁliated laboratory for testing. Only ﬁve of the nine surveyed
rganizations have a system in place for remote testing; other
rganizations indicated that they provide such support on a case-
y-case basis. infection status in participants with VISR. The tests may not differentiate between
articipants with VISR may be incorrectly perceived as being HIV-positive. Because
atus may  lead to delayed diagnosis of infection.
Recommended: trial sponsors to establish procedures to
provide accurate HIV testing to all participants for as long as
needed.
Unknowns about the frequency and durability of VISR make
it challenging for trial sponsors to plan and budget for long-term
testing. As the number of participants in HIV vaccine clinical trials
increases, the cost to manage long-term HIV testing for participants
is expected to become a major expense for clinical trial programs.
Recommended: the HIV vaccine ﬁeld, together with regulatory
authorities and public health agencies, to set aside contingency
resources to assure that trial records are maintained and all testing
needs are met  in the future, independent of funding availability for
individual programs.
3.3. Conﬁrming trial participation
All clinical trial organizations maintain records with identiﬁers
and study regimens that can verify a person’s participation in the
vaccine arm of a study. However, since the records are usually
maintained by the trial sites, it may  be difﬁcult for participants to
gain access to the information if the site closes or the participant
relocates. The HVTN has addressed this issue by creating the “VISP
Testing Service” [15] with a toll free number for the US (and soon
for South Africa) distributed in emails and brochures and posted on
the HVTN website to ensure participants have a permanent contact
with the sponsor.
Recommended: trial sponsors to provide a permanent point of
contact for all trial participants to obtain conﬁrmation of participa-
tion in the vaccine arm of a study.
Because records are not kept in a centralized location, the time
to access records may  vary depending on the responsiveness of the
trial site. To quickly identify former trial participants, some orga-
nizations have created dedicated registries in which the name of
the participant is readily matched to the study regimen and iden-
tiﬁers. The HVTN, for example, created the “VISP Registry” [15]
and recently mandated that all trial participants be included in the
registry. The United States Army Medical Research and Materiel
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Table 1
Study participants with VISR may  experience social harms associated with the misunderstanding of their HIV status.
Area of daily life Potential social harms Comments
Personal relationships and stigma in
the society
Family members, loved ones, and co-workers may
have negative reactions to trial participation or
misinterpret VISR as true HIV infection.
The stigma of being associated with HIV ‘positivity’
was reported as a major concern for potential trial
volunteers [23,24] and was  the main social harm in the
CAB consultations conducted by the Enterprise.
Employment Employers may  discriminate against a potential
employee perceived as being HIV positive.
Reported cases have been rare, but the potential
impact is serious [25,26].
Insurance (medical/dental, disability,
or life)
In some countries, insurance companies may request
an  HIV test from an applicant to check for pre-existing
conditions and could deny insurance or charge a higher
premium from a person perceived to be HIV-infected.
Trial sponsors can intervene by providing conﬁrmation
of  participation and true HIV status; however,
companies are not legally compelled to accept test
results from CRSs.
The insurance industry of the Republic of South Africa
has implemented guidelines for HIV testing of
individuals applying for insurance who identify as HIV
vaccine study participants. These testing guidelines are
incorporated into laboratory test requisitions [27].
Travel  – immigration A volunteer with VISR may  be denied a visa as a result
of an HIV test during the medical exam portion of a
visa application [28,29].
For a small number of countries that require an HIV
test for entry, visa applicants with VISR should contact
the  embassy of the destination country and inquire if
an HIV test result from a speciﬁc laboratory is
acceptable or if they need to contact the trial sponsor
for assistance in providing comprehensive
documentation of their true HIV status.
International travelers may also beneﬁt from alerting
their own country’s consulate in the event that further
assistance is needed once abroad.
Military career, blood banking within
military, and deployment
For some countries with high prevalence, HIV infection
is  not exclusionary to military service.
In  the US, individuals with VISR are ineligible to join
the military. If already enrolled, they cannot be
deployed because they cannot be blood donors in the
ﬁeld [30,31].
Potential trial volunteers in the US  need to be clearly
informed that development of VISR may  make them
ineligible to serve in the US military and eliminate
military service as a career option for the foreseeable
future.
Keefer et al. reported a case that was resolved after the
trial sponsor established HIV-negative status [32].
US  soldiers are excluded from enrollment in the
military’s own HIV vaccine trials [33].
Blood,  organ, stem cell, and sperm
donations
A person with VISR may be rejected on the basis of
testing uncertainty. The inability to donate may  be
considered a social harm by volunteers and may  also
prevent lifesaving medical procedures for loved ones
and patients in critical conditions.
In France and the USA, volunteers with VISR are not
allowed to donate blood.
In Thailand, trial volunteers must produce proof that
they were enrolled in the placebo arm of an HIV
vaccine trial to be able to donate blood.
Conﬁrmation of HIV-negative status of a participant
with VISR may  not change the exclusion from blood
donation per Red Cross guidelines [34].
Newborn HIV prophylaxis in the
context of PMTCT
A newborn in the clinic or hospital may  be given
antiretroviral drugs as prophylaxis if the mother has
VISR and is tested with a rapid test during labor.
One case is known in the US wherein a newborn was
placed on ART due to the mother’s VISR. ART was
discontinued after the mother self-identiﬁed as a
vaccine volunteer, the trial site conﬁrmed study
participation, and conﬁrmatory tests were conducted
[35]. There was another case in the US where a
newborn was about to be placed on ART due to the
mother’s VISR status despite the mother
self-identifying as a vaccine trial volunteer; initiation
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sommand (USAMRMC) in the US and Thailand also collects data
rom all trial participants into the ‘Volunteer Registry Database’.
While the creation of regional or national study participant reg-
stries has been strongly advised by some, it faces a number of
hallenges: merging data from different trial organizations into a
ommon secure database is technically complex, in-country regu-
atory authorities and ethics committees need to be consulted, and
uch registries must comply with local privacy laws.
Recommended: trial sponsors to consider creating a secure
articipant registry to facilitate access to records, including cross-
ponsor regional or national registries.
Once trial participation is conﬁrmed, trial sponsors can com-
unicate on behalf of the participant and/or issue documentation
uch as a “certiﬁcate of trial participation” to help the participantsof ART was avoided after the trial site was contacted,
and conﬁrmatory tests were conducted [36].
demonstrate their need for specialized HIV testing. The certiﬁ-
cate is a portable identiﬁer that documents past participation in
a vaccine study, but cannot attest to the current HIV status of
the individual. For example, the NIAID Vaccine Research Program
offers photo ID cards that indicate participation in a trial (the word
“HIV” is not included to reduce the chances of stigmatization)
and provide contact information for the CRS. However, individ-
uals may  decline the card or be uncomfortable carrying such a
document.3.4. Raising awareness about the existence and impact of VISR
Information about VISR frequency, duration, and impact on life
needs to be gathered and disseminated to relevant stakeholders.
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Table  2
Examples of variability in VISR incidence and duration. For the same candidate vaccine, VISR rates can vary greatly depending on which test is used (1-a vs. 1-b and 1-c;
2-a  vs.2-b; 4-a vs.4-b) and by treatment groups. A 10-fold difference in the dose of one component can drastically inﬂuence the rate of VISR detected by the same test (6-a
vs.6-b). *NA: Data not available
Vaccine trial and regimen HIV assay Incidence of VISR at end of
study (6 months)
Durability of VISR over
time
1
VRC DNA/Ad5 - EnvABC, Gag, Pol (Nef)
HVTN204 [33]
a Bio-Rad GS HIV 1/2 Plus O EIA 6% 0% after 5 years
b  Abbott HIVAB HIV-1/HIV-2 (rDNA) EIA 85.8% NA
c  Abbott AxSYM HIV Ag/Ab Combo NA* 84.3% after 5 years
2
Ad26-EnvA/Ad35-EnvA
HVTN 910 (IAVI B003) [33]
a Bio-Rad Multispot HIV-1/HIV-2 Rapid Test 12.5% NA
b  bioMerieux Vironostika HIV Ag/Ab 96.8% NA
3
ALVAC-HIV vCP125/gp160
gp160/peptide V3
ANRS VAC01 and VAC02 [21]
Bio-Rad Genscreen ULTRA HIV Ag-Ab NA 33% after 16.5 years
Biotest Anti-HIV TETRA ELISA NA 44% after 16.5 years
4
ALVAC-HIV vCP1452 or
vCP205
ANRS VAC03 and VAC10 [21]
a Bio-Rad Genscreen ULTRA HIV Ag-Ab NA 0% after 8 years
b  Biotest Anti HIV TETRA ELISA NA 18% after 8 years
5  ALVAC-HIV (vCP1521)/AIDSVAX B/E
MHRP RV144 [11]
bioMerieux Vironostika HIV Ag/Ab 0.4% NA
6
rAd5 109 VLP/NYVAC-B/NYVAC-B
HVTN078, Treatment Group 3 [33]
a Abbott ARCHITECT HIV Ag/Ab Combo 0.0% NA
3
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IrAd5  1010 VLP/NYVAC-B/NYVAC-B
HVTN078, Treatment Group 4 [33]
b 
.4.1. Scientiﬁc community
While it is impossible to predict the frequency and duration of
ISR before a trial, clinical researchers need to be prepared to pre-
ent and mitigate various social harms encountered by participants
ith VISR. Multiple groups have presented at conferences and pub-
ished peer-reviewed articles on the rate and durability of VISR in
rial participants, as well as on social harms [16–21].
Five clinical trial organizations offer participants the opportu-
ity to enroll in long-term follow-up (LTFU) observational studies
nce the trial is closed. These studies are IRB approved and can
e used for research purposes, including research on the incidence
nd duration of VISR and the nature of social harms. Such trials may
elp clarify the actual needs of participants with VISR in the future.
articipants can be followed either for a set number of years or
or an open-ended period, as in the HVTN 910 protocol [15]. While
ll organizations encourage enrollment in LTFU studies, access to
esting is not contingent on participation.
able 3
urrent practices that organizations conducting HIV vaccine trials use to address VISR.a
Survey question 
Inform participants of the potential for VISR and how it may  impact their lives
The  protocol informed consent describes VISR and associated risks 
Provide accurate testing for former trial participants who have VISR
End of study HIV testing to asses risk of VISR, performed with locally available tests 
Post-study differential VISR vs. HIV infection testing provided as long as needed 
Participants who relocate can access VISR vs. HIV infection testing remotely 
A  long-term mode for contact is provided in the event that CRS closes 
Help  manage any social harms that occur as a result of the participant’s VISR status
The protocol collects laboratory data on VISR 
The  protocol collects data on VISR related social impact 
Post-study enrollment in long-term follow up study offered 
Assistance is provided to participants with VISR in regards to social harms 
Research staff maintains records with identiﬁers and study regimen of participants wh
support with VISR related issues
Inform scientists, health care providers, and the community about the existence of
Information about VISR was presented at meetings attended by investigators and healt
practitioners
Data about VISR was published in scientiﬁc journals 
In-country blood banks have been informed about VISR 
a Survey conducted by NIAID and the Global HIV Vaccine Enterprise (2013–2014). Organ
esearch Institute, France; China CDC: Chinese Center for Disease Control, China; EDCTP
AVI:  International AIDS Vaccine Initiative, US; HVTN: HIV Vaccine Trials Network, US; UK46.7% NA
The data on VISR will continue to evolve as new vaccine
candidates and HIV tests are developed. The data regarding
country-speciﬁc challenges remain sparse.
Recommended: the research community to continue to study
VISR and publish systematic studies and case reports to enable
clinical researchers to better anticipate, prevent, and mitigate the
impact of VISR on participants.
3.4.2. Healthcare providers
Education of healthcare providers could signiﬁcantly reduce
VISR-related issues. When HIV testing is performed at the doc-
tor’s ofﬁce, the physician who knows to ask about the patient’s
past or current participation in a vaccine trial can avoid potential
misdiagnosis and unnecessary treatment. Physicians should also
be aware of the availability of differential testing performed by
trial sponsors. As an example, the FHCRC/University of Washing-
ton Vaccine CRS, located in Seattle, WA,  worked with public health
# of organizations answering YES
9
9
9
5
7
9
5
5
9
o may  need 9
2 Registries
 VISR
hcare 8
7
5
izations participating: ANRS: Agence Nationale de Recherche sur le SIDA – Vaccine
: European and Developing Countries Clinical Trials Partnership, The Netherlands;
 HVC: HIV Vaccine Consortium, UK; US MHRP: Military HIV Research Program, US.
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Box 1: Summary of recommendations
It is recommended that
• Trial sponsors strongly advise all participants to inform their
primary care physician about their participation in an HIV
vaccine trial and the possibility of VISR
• Trial sponsors establish procedures to provide accurate HIV
testing to all participants for as long as needed
• The HIV vaccine ﬁeld, together with regulatory authori-
ties and public health agencies, to set aside contingency
resources to assure that trial records are maintained and all
testing needs are met  in the future, independent of funding
availability for individual programs
• Trial sponsors to provide a permanent point of contact for
all trial participants to obtain conﬁrmation of participation in
the vaccine arm of a study
• Trial sponsors to consider creating a secure participant reg-
istry to facilitate access to records, including cross-sponsor
regional or national registries
• The research community to continue to study VISR and pub-
lish systematic studies and case reports to enable clinical
researchers to better anticipate, prevent, and mitigate the
impact of VISR on participants
• Trial sponsors to inform and educate healthcare providers
about VISR in the areas where sponsors are conducting clin-
ical trials
• In-country health authorities to ensure that national guide-
lines for HIV testing identify VISR as a potential confounder
for interpreting serological test results
• Test manufacturers to include language about the possibil-
ity of VISR interference with testing in package inserts for
[
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uthorities in Washington State to incorporate VISR education into
tate-mandated healthcare provider training, including the health
epartment’s training sessions on HIV testing and counseling [15].
ebsites, such as the public section of HVTN’s website on VISP [22],
an be a useful resource both to physicians and to participants.
Recommended: trial sponsors to inform and educate healthcare
roviders about VISR in the areas where sponsors are conducting
linical trials.
.4.3. HIV testing
In 2006, the US CDC published its Revised Recommendations
or HIV Testing of Adults, Adolescents, and Pregnant Women  in
ealth-Care Settings, which speciﬁcally mentions participants in
IV vaccine trials: “Recipients of preventive HIV vaccines might have
accine-induced antibodies that are detectable by HIV antibody tests.
ersons whose test results are HIV positive and who are identiﬁed as
accine trial participants might not be infected with HIV and should
e encouraged to contact or return to their trial site or an associated
rial site for the conﬁrmatory testing necessary to determine their HIV
tatus” [14]. Similar considerations are expected to be included in
he updated 2014 guidelines (personal communication to authors
rom Michele Owen, CDC).
Recommended: in-country health authorities to ensure that
ational guidelines for HIV testing identify VISR as a potential con-
ounder for interpreting serological test results.
In the US, the FDA works with manufacturers to include the fol-
owing language about VISR in package inserts for HIV serological
ests: “A person who has antibodies to HIV-1 is presumed to be infected
ith the virus except that a person who has participated in an HIV vac-
ine study may  develop antibodies to the vaccine and may or may not
e infected with HIV.” The World Health Organization could play a
ole in helping to ensure that similar advisory language is imple-
ented worldwide, e.g. through its prequaliﬁcation processes for
edicinal products, including diagnostic tests.
Recommended: test manufacturers to include language about
he possibility of VISR interference with testing in package inserts
or commercially available serological HIV tests worldwide.
. Conclusions
VISR may  be viewed as a straightforward challenge that can
e addressed using available technologies. However, the unpre-
ictable nature of the phenomenon, its potentially long duration,
nd the complexity of social interactions associated with HIV
esting make the delivery of these technologies expensive and
ogistically challenging. Trial sponsors recognize an ethical obliga-
ion to support trial participants to the best of their abilities, and
any sponsors currently spend considerable resources to study
nd mitigate the potential harms encountered by participants with
ISR. However, more long-term and universally applicable solu-
ions are needed. In this article, we aimed to identify the gaps in
he current landscape as well as the stakeholders best positioned to
ake action in each area (Box 1). These recommendations may  serve
s a ﬁeld-wide roadmap to a coordinated effort and as a baseline
or assessing the state of the ﬁeld in the future.
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